Management of prostate cancer. Part 1: chemoprevention

Expert Review of Anticancer Therapy
Prasanna Sooriakumaran

Abstract

Numerous agents have been investigated in prostate cancer prevention. Many manipulate sex steroid levels or function, some regulate response to oxidative stress and others affect tumor proliferation and/or apoptosis. Some are postulated to even affect downstream targets, such as cyclooxygenase-2, which has been shown to be elevated in prostate cancer by most investigators. The evidence for all these potential chemopreventive agents is critically reviewed. While the current information base is vast, level 1 evidence is lacking, and ongoing trials are not due to provide such evidence for many years to come. In addition, the current lack of ability to accurately differentiate clinically important prostate cancer from latent disease makes chemoprevention in this setting even more challenging. Currently, no reliable biomarkers that can act as surrogate endpoints for the development of clinically relevant prostate cancer exist, which makes performing large chemoprevention trials expensive. At present, there is little to suggest that the urologist or General Practitioner should be recommending any particular chemopreventive agent to either the general population or those deemed to be at higher risk of contracting prostate cancer.

References

Mar 1, 1979·The Journal of Clinical Investigation·R J MooreJ D Wilson
Nov 15, 1977·International Journal of Cancer. Journal International Du Cancer·N BreslowH Tulinius
Jun 6, 1990·Journal of the National Cancer Institute·A W HsingB F Polk
Jul 1, 1985·American Journal of Reproductive Immunology and Microbiology : AJRIM·M W ShawC F McKiel
Apr 1, 1985·Food Additives and Contaminants·K R Price, G R Fenwick
Jul 31, 1985·Biochemical and Biophysical Research Communications·M M WebberG T James
Jun 15, 1982·International Journal of Cancer. Journal International Du Cancer·R YataniP Correa
Dec 6, 1995·Journal of the National Cancer Institute·E GiovannucciW C Willett
Dec 1, 1995·The American Journal of Clinical Nutrition·M G Traber, L Packer
Oct 4, 1995·Journal of the National Cancer Institute·Y WangW D Heston
Feb 16, 1994·Journal of the National Cancer Institute·P H GannM J Stampfer
Nov 20, 1997·The Prostate·I M ThompsonJ Crowley
Mar 21, 1998·The Journal of Urology·I BairatiL Moore
Aug 27, 1998·Journal of the National Cancer Institute·K YoshizawaE Giovannucci
Sep 28, 1998·The Journal of Steroid Biochemistry and Molecular Biology·M BlanchereI Mowszowicz
Mar 24, 1999·Journal of the National Cancer Institute·P MukherjeeS K Clinton
May 15, 1999·European Urology·L DenisK Griffiths
Aug 10, 2000·Cancer·R YoshimuraS Wada
Sep 26, 2001·Neoplasia : an International Journal for Oncology Research·S B ShappellA R Brash
Mar 13, 2002·Mayo Clinic Proceedings·Rosebud O RobertsSteven J Jacobsen
Jul 31, 2002·Cancer Causes & Control : CCC·Laurel A HabelJanet L Stanford
Nov 9, 2002·Experimental Biology and Medicine·David Heber, Qing-Yi Lu
Dec 21, 2002·International Journal of Cancer. Journal International Du Cancer·Tara M VogtSusan T Mayne
Jan 10, 2003·Journal of Cellular Biochemistry·Aruna V KrishnanDavid Feldman
Jun 26, 2003·The New England Journal of Medicine·Ian M ThompsonCharles A Coltman
Jul 4, 2003·The Journal of Nutrition·Vaqar M AdhamiHasan Mukhtar
Jul 4, 2003·The Journal of Nutrition·Donna M PeehlDavid Feldman
Jul 8, 2003·International Journal of Cancer. Journal International Du Cancer·Linda PerronFrançois Meyer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis